ALS 2-0426
Phase 2- Indications
- Type 2 diabetes
Company intelligence / Profile preview
Alantos Pharmaceuticals
Cambridge, Massachusetts, United Statesamgen.com ↗
- Ownership
- Private
- Employees
- ~45
- Development stage
- Phase 2
01
Overview
Alantos’ lead candidate was ALS 2-0426, a DPP-IV inhibitor in Phase 2a for type II diabetes. The company also had a matrix metalloproteinase inhibitor platform targeting osteoarthritis and several preclinical programs focused on inflammation and metabolic diseases. Amgen acquired the company in mid-2007 for $300 million to expand its pipeline with these assets.
- Therapeutic areas
- OncologyEndocrinologyImmunologyDermatologyRheumatologyGastroenterologyCardiovascular
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major disclosed partnerships
Beyond the preview
Go deeper on Alantos Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alantos Pharmaceuticals.